KDR and gastric cancer: Apatinib mesylate is a small molecule VEGFR-2 tyrosine kinase inhibitor and was the first small molecule targeted drug proven to improve the survival rate of patients with gastric cancer, hepatocellular carcinoma, and non-small-cell lung cancer (21).